Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym021 Monotherapy and Combinations in Advanced Solid Tumors
NCT03311412Phase 1Completed
- Sponsor
- Symphogen
- Start
- Nov 2017
- Primary completion
- Mar 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of sym021 in solid tumor and lymphoma, sponsored by Symphogen. Primary endpoint: Dose-Limiting Toxicities at 12 months. Started Nov 2017; status: completed.
02
Drugs
sym021
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03311412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311412.